Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis

Fig. 2

The efficacy of Adalimumab to treat JIA-related uveitis. The efficacy of Adalimumab was assessed in 1289 patients. The pooled response rate to Adalimumab was estimated to be 68.0% (95%CI: 65.4 to 70.6%). Assessment of the studies on the efficacy of Adalimumab indicated that the statistical heterogeneity was significant with an I2 of 57.164%

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172